# Sanyou Biopharmaceuticals Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sanyou-biopharmaceuticals-co

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.sanyoubio.com
- Latest round: Series B (Aug 2, 2022)
- Investors on record: 9

## About

Based in Shanghai, China and founded in 2015, Sanyou Biopharmaceuticals Co., Ltd. is a pharmaceutical company that focuses on development of innovative monoclonal antibody drugs, providing therapeutic antibody discovery and relevant technology platforms. The company has established global business centers across Asia, North America, and Europe and has filed over 130 invention patents. It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai “Specialized and Innovative” Enterprise, ISO9001, and ISO27001.

In February 2026, returning investor Shanghai ZJ Bio-Tech Co., Ltd. and new investor Yanghe Biomedicine Industry Investment partly acquired Sanyou Biopharmaceuticals Co., Ltd. from Haier Capital.

The company has built an integrated drug development platform, mainly including innovative antibody drugs, target-to-PCC drugs, PCC-to-IND drugs and other research and development platforms, the innovative antibody drug discovery platform include integrated protein and antigen preparation technology, systematic antibody drug functional screening technology, large-capacity phage display full antibody library technology, innovative antibody engineering technology, diversified antibody production technology and integrated genetic engineering antibody library technology, and has self-develop a COVID-19 proteins and antibodies in 2020. The company also provides high-quality proteins, antibodies, cell lines and detection reagents.

The company generates revenue from providing integrated antibody drug development platforms.

The funding from Shanghai ZJ Bio-Tech Co., Ltd. and Yanghe Biomedicine Industry Investment is expected to further optimize Sanyou Biopharmaceuticals Co., Ltd.'s governance structure and deepen industrial synergy. With this deal, investors and target company will fully leverage their existing strategic advantages to deepen collaborative research in the field of innovative biopharmaceutical R&D, further shorten the R&D cycle, improve R&D efficiency, and enhance core competitiveness.

## Funding rounds

- Series B, Aug 2, 2022 — Shenzhen Qianhai Beizeng Asset Management, Seeking Capital, Jiangsu Zijin Hongyun Health Industry Investment Partnership, Nanjing Huatai Guoxin Medical Investment Partnership
- Series B, Jun 26, 2021 — Seeking Capital, LH Ventures, Grand Mount Capital, Grand Mount Capital, Motianshi Investment
- Series A, May 16, 2020 — Haier Capital, Shanghai ZJ Bio-Tech Co., Ltd.
- Series A, Dec 7, 2017 — Seeking Capital

## Investors

- Seeking Capital (https://capitalatlas.ai/funds/seeking-capital) — Series A, Series B
- Haier Capital (https://capitalatlas.ai/funds/haier-capital) — Series A
- Shanghai ZJ Bio-Tech Co., Ltd. — Series A
- LH Ventures (https://capitalatlas.ai/funds/lh-ventures) — Series B
- Grand Mount Capital (https://capitalatlas.ai/funds/grand-mount-capital) — Series B
- Motianshi Investment — Series B
- Shenzhen Qianhai Beizeng Asset Management (https://capitalatlas.ai/funds/shenzhen-qianhai-beizeng-asset-management) — Series B
- Jiangsu Zijin Hongyun Health Industry Investment Partnership — Series B
- Nanjing Huatai Guoxin Medical Investment Partnership — Series B